Ceryvyn Therapeutics (ASX:CYV) Change In Receivables: A$0.00 Mil (TTM As of Jun. 2025)


What is Ceryvyn Therapeutics Change In Receivables?

Ceryvyn Therapeutics ASX:CYV -7.69% Change In Receivables is A$0.00 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Ceryvyn Therapeutics's change in receivables for the quarter that ended in Jun. 2025 was A$0.00 Mil. It means Ceryvyn Therapeutics's Accounts Receivable stayed the same from Dec. 2024 to Jun. 2025 .

Ceryvyn Therapeutics's change in receivables for the fiscal year that ended in Jun. 2025 was A$0.00 Mil. It means Ceryvyn Therapeutics's Accounts Receivable stayed the same from Jun. 2024 to Jun. 2025 .

Ceryvyn Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2025 was A$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ceryvyn Therapeutics's Days Sales Outstanding for the six months ended in Jun. 2025 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ceryvyn Therapeutics's liquidation value for the six months ended in Jun. 2025 was A$-321.68 Mil.

Ceryvyn Therapeutics  (ASX:CYV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ceryvyn Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0.002*91
=0.00

2. In Ben Graham's calculation of liquidation value, Ceryvyn Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Ceryvyn Therapeutics's liquidation value for the quarter that ended in Jun. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=74.408-396.085+0.75 * 0+0.5 * 0
=-321.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Change In Receivables Related Terms

Ceryvyn Therapeutics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Change In Receivables Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.48 0.00 0.00 0.00 0.00

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ceryvyn Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of A$0.00 Mil mean?
Ceryvyn Therapeutics (ASX:CYV) has a Change In Receivables of A$0.00 Mil as of Jun. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Change In Receivables too high?
Ceryvyn Therapeutics' current Change In Receivables is A$0.00 Mil.
How does Ceryvyn Therapeutics' Change In Receivables compare to VRTX and REGN?
Ceryvyn Therapeutics' Change In Receivables of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Change In Receivables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Change In Receivables of A$0.00 Mil. The current Change In Receivables is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Change In Receivables is A$0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.